Preclinical results define approach for GO-203 administration in novel nanoparticles to target MUC1-C in human cancers

​Preclinical results of MUC1-C-targeted GO-203/nanoparticles published in the journal “Clinical Cancer Research”.  These findings define an approach for sustained administration of GO-203 in novel polymeric tetra block nanoparticles to target MUC1-C in human cancers.